Calcium channel blockers exist in short- and long-acting forms. Short-acting medications yield faster results than their long-acting counterparts. Amlodipine, Diltiazem, Felodipine, Isradipine, and Nicardipine are calcium channel blockers used to treat coronary artery disease, angina, arrhythmias, and conditions like Raynaud's disease.
The global market for calcium channel blocker drugs is predicted to experience growth due to the rising prevalence of hypertension. Hypertension is a leading cause of premature death globally, affecting a significant number of adults, including a large population in the U.S., where millions of individuals require medication and lifestyle changes to manage the condition.
In 2022, the estimated value of the global market for Calcium Channel Blocker Drugs is US$ 14,285.3 million, with a projected compound annual growth rate (CAGR) of 5.2% from 2022 to 2030.
Top Companies in the Calcium Channel Blocker Drugs Industry:
1. Bausch Health
Bausch Health was established in 1959 and is headquartered in Laval, Canada. It has operations in more than 90 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceuticals.
2. Mylan N.V.
Mylan N.V. was established in 1961 and is headquartered in Canonsburg, Pennsylvania, U.S. It has operations in 165 countries and is engaged in various industries, including biotechnology, healthcare, life science, and pharmaceuticals.
3. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. was established in 1944 and is headquartered in Tel Aviv, Israel. It has operations in 60 countries and is engaged in various industries, including biopharma, healthcare, medical, and pharmaceuticals.